

LEUCODININE B 10%

Mequinol ointment

Local treatment of acquired melanin hyperpigmentations, in particular: melasma, post-inflammatory or chemical (parfume) melanosis

FORMS and PRESENTATIONS

Ointment: Tube of 30 g.

COMPOSITION

Per tube

Mequinol (INN) 3 g

Excipients: macrogol 300, macrogol 1 500.

INDICATIONS

Local treatment of acquired melanin hyperpigmentations, in particular: melasma, post-inflammatory or chemical (parfume) melanosis.

DOSAGE AND ADMINISTRATION

2 applications per day.

The frequency of application can be reduced as improvement is seen. When depigmentation is obtained, it is preferable to continue using the treatment at least once a week. Local photoprotection is necessary.

CONTRAINDICATIONS

Hypersensitivity to mequinol.

Children under 12 years.

WARNINGS and PRECAUTIONS FOR USE

Avoid sun exposure of hyperpigmented areas or ensure local photoprotection by using a total sunscreen cream both during and after treatment.

Avoid contact with eyes and mucous membranes.

PREGNANCY and LACTATION

Pregnancy:

In exposed pregnancies, no fetal malformation or toxicity has been reported to date. However, the follow-up of pregnancies exposed to mequinol is insufficient to rule out a risk.

Therefore, as a precaution, this medicinal product should preferably not be used during pregnancy.

Lactation:

In the absence of data, the use of this medicinal product should be avoided during lactation.

UNDESIRABLE EFFECTS

Irritation or sensitization reactions to mequinol (rare).

Risk of post-inflammatory hypermelanosis.

Cases of nonhomogeneous leukomelanoderma en confetti at the application site, and hypomelanosis occurring far from the treated areas, have been reported.

PHARMACODYNAMICS

Translator : [there seems to be a mistake here](#) Réactions à type d'irritation ou de sensibilisation au méquinol (rare).

Risque d'hypermélanose post-inflammatoire.

Des cas de leucomélanodermie inhomogène avec dépigmentation en confettis au site d'application et quelques cas d'hypomélanose survenant à distance des zones traitées ont été rapportés.

INCOMPATIBILITIES

Do not mix with other creams or ointments (risk of incompatibility, in particular with oxidants or metallic compounds).

PRESCRIPTION/SUPPLY/REIMBURSEMENT

Marketing Authorization No. 306 134.4 (1962/96).

Not reimbursed by national health insurance.

Marketing Authorization Holder: CLS Pharma. contact@clspharma.fr